An open-label phase II study evaluating the safety and efficacy of PTK787/ZK222584 [vatalanib] in patients with metastatic neuroendocrine tumors that have evidence of progressive disease or an increase in disease related syndrome symptoms.

Trial Profile

An open-label phase II study evaluating the safety and efficacy of PTK787/ZK222584 [vatalanib] in patients with metastatic neuroendocrine tumors that have evidence of progressive disease or an increase in disease related syndrome symptoms.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2011

At a glance

  • Drugs Vatalanib (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 28 Jun 2011 Actual initiation date changed from Dec 2006 to Nov 2004 as reported by ClinicalTrials.gov.
    • 28 Jun 2011 Actual initiation date changed from Dec 2006 to Nov 2004 as reported by ClinicalTrials.gov.
    • 02 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top